Charlotte Skoglund1, Qi Chen2, Johan Franck3, Paul Lichtenstein2, Henrik Larsson2. 1. Departments of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.. Electronic address: charlotte.skoglund@ki.se. 2. Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 3. Departments of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Previous research indicates that attention-deficit/hyperactivity disorder (ADHD) is highly associated with substance use disorders (SUD). However, these studies have failed to clarify the nature of the overlap. The main aim of this study was to explore whether the overlap between ADHD and SUD could be explained by shared genetic and environmental factors or by harmful effects of ADHD medication. METHODS: We employed a matched cohort design across different levels of family relatedness recorded from 1973-2009. By linking longitudinal Swedish national registers, 62,015 ADHD probands and first-degree and second-degree relatives were identified and matched 1:10 with control subjects without ADHD and their corresponding relatives. Any record of SUD was defined by discharge diagnoses of the International Classification of Diseases or a purchase of any drug used in the treatment of SUD. RESULTS: First-degree relatives of ADHD probands were at elevated risk for SUD (odds ratios 2.2 and 1.8) compared with relatives of control subjects. The corresponding relative risk in second-degree relatives was substantially lower (odd ratios 1.4 and 1.4). The familial aggregation patterns remained similar for first-degree and second-degree relatives after excluding individuals with coexisting disorders such as schizophrenia, bipolar disorder, depression, and conduct disorder. CONCLUSIONS: Our findings suggest that the co-occurrence of ADHD and SUD is due to genetic factors shared between the two disorders, rather than to a general propensity for psychiatric disorders or harmful effects of ADHD medication.
BACKGROUND: Previous research indicates that attention-deficit/hyperactivity disorder (ADHD) is highly associated with substance use disorders (SUD). However, these studies have failed to clarify the nature of the overlap. The main aim of this study was to explore whether the overlap between ADHD and SUD could be explained by shared genetic and environmental factors or by harmful effects of ADHD medication. METHODS: We employed a matched cohort design across different levels of family relatedness recorded from 1973-2009. By linking longitudinal Swedish national registers, 62,015 ADHD probands and first-degree and second-degree relatives were identified and matched 1:10 with control subjects without ADHD and their corresponding relatives. Any record of SUD was defined by discharge diagnoses of the International Classification of Diseases or a purchase of any drug used in the treatment of SUD. RESULTS: First-degree relatives of ADHD probands were at elevated risk for SUD (odds ratios 2.2 and 1.8) compared with relatives of control subjects. The corresponding relative risk in second-degree relatives was substantially lower (odd ratios 1.4 and 1.4). The familial aggregation patterns remained similar for first-degree and second-degree relatives after excluding individuals with coexisting disorders such as schizophrenia, bipolar disorder, depression, and conduct disorder. CONCLUSIONS: Our findings suggest that the co-occurrence of ADHD and SUD is due to genetic factors shared between the two disorders, rather than to a general propensity for psychiatric disorders or harmful effects of ADHD medication.
Authors: Isabell Brikell; Laura Ghirardi; Brian M D'Onofrio; David W Dunn; Catarina Almqvist; Søren Dalsgaard; Ralf Kuja-Halkola; Henrik Larsson Journal: Biol Psychiatry Date: 2017-08-12 Impact factor: 13.382
Authors: Patrick D Quinn; Erik Pettersson; Sebastian Lundström; Henrik Anckarsäter; Niklas Långström; Clara Hellner Gumpert; Henrik Larsson; Paul Lichtenstein; Brian M D'Onofrio Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2015-12-30 Impact factor: 3.568
Authors: Patrick D Quinn; Zheng Chang; Kwan Hur; Robert D Gibbons; Benjamin B Lahey; Martin E Rickert; Arvid Sjölander; Paul Lichtenstein; Henrik Larsson; Brian M D'Onofrio Journal: Am J Psychiatry Date: 2017-06-29 Impact factor: 18.112
Authors: Amy M Yule; MaryKate Martelon; Stephen V Faraone; Nicholas Carrellas; Timothy E Wilens; Joseph Biederman Journal: J Psychiatr Res Date: 2016-10-22 Impact factor: 4.791
Authors: Allison M Momany; Jaclyn M Kamradt; Josie M Ullsperger; Alexis L Elmore; Joel T Nigg; Molly A Nikolas Journal: J Abnorm Psychol Date: 2016-11-17
Authors: Ran S Rotem; Gabriel Chodick; Michael Davidovitch; Andrea Bellavia; Marc G Weisskopf Journal: Am J Epidemiol Date: 2022-02-19 Impact factor: 4.897
Authors: Sonja LaBianca; Jette LaBianca; Anne Katrine Pagsberg; Klaus Damgaard Jakobsen; Vivek Appadurai; Alfonso Buil; Thomas Werge Journal: J Autism Dev Disord Date: 2021-01
Authors: Charlotte Skoglund; Lena Brandt; Catarina Almqvist; Brian M DʼOnofrio; Maija Konstenius; Johan Franck; Henrik Larsson Journal: J Clin Psychopharmacol Date: 2016-06 Impact factor: 3.153
Authors: Honghuang Lin; Fan Wang; Andrew J Rosato; Lindsay A Farrer; David C Henderson; Huiping Zhang Journal: Epigenomics Date: 2020-06-04 Impact factor: 4.778